You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Optical photothermal IR (O-PTIR) microscopy for chemical imaging of living cells at sub-micron resolution

    SBC: PHOTOTHERMAL SPECTROSCOPY CORP.            Topic: 102

    Optical photothermal IR (OPTIR) microscopy for chemical imaging of living cells at sub-micron resolution Project Summary/Abstract Photothermal Spectroscopy Corp (PSC) and Prof. Ji-Xin Cheng of Boston University in collaboration with Prof. Rohith Reddy (University of Houston) propose to develop, validate, and commercialize a novel technical called Optical Photothermal Infrared (OPTIR) spectroscopy. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems

    SBC: Prentke Romich Company            Topic: NIDCD

    Compatibility between Brain-Computer Interface and High Efficiency Augmentative and AlternativeCommunication Systems: Phase II ABSTRACT Brain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY State of the art techniques result inyear solid organ graft loss ofto overin cardiopulmonary organ transplantationEstablishment of donor specific immunological toleranceDSITa condition in which a recipient accepts a transplant without immunosuppressionwhile retaining the ability to fight infectionswould reduce graft loss and transplant related complicationsThe only identified metho ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Black Bear Parathyroid Hormone as an Anabolic Agent for Bone

    SBC: PROTEOS, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Project Summary/Abstract. A clinical need exists for better osteoporosis treatments since only one anabolic therapy (truncated recombinant human parathyroid hormone 1-34, teriparatide/Forteo(R)) is commercially available. Bears possess the unique ability to prevent bone loss during physical inactivity (hibernation) by maintaining balanced bone remodeling; the b ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania

    SBC: HAMZTEC, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): The goal of the proposed research is to further refine and evaluate an inconspicuous, awareness- enhancement and monitoring device (AEMD) which will assist the treatment of trichotillomania (TTM). TTM is associated with significant impairments in social functioning and often has a profound negative impact on self- esteem and well being. Conservative estimates s ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Internet-based Fidelity Enhancement of MTFC

    SBC: Tfc Consultants, Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Low cost custom synthesis microarray

    SBC: BIODISCOVERY LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): The results of our very successful phase I project showed that using projection lithography and off the shelf oligonucleotide synthesis reagents, we could in situ synthesize high density, high quality, very low cost, custom oligonucleotide microarrays on simple open substrates such as microscope slides. We also showed that using silver staining amplification it ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government